Klaus Strebhardt

17PUBLICATIONS
33CO-AUTHORS
Molecular targetsPredictive and prognostic markersReaction engineering (excl. nuclear reactions)Cancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 28, 2026
Correction: Raab et al. Truncated DAPK Variants Restore Tumor Suppressor Activity and Synergize with Standard Therapies in High-Grade Serous Ovarian Cancer. Cancers 2025, 17, 1910.

|May 16, 2025
Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.

Danda Chapagai, Klaus Strebhardt, Michael D Wyatt

|Jan 11, 2024
Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors.

Khayal Gasimli, Monika Raab, Ranadip Mandal

|Dec 23, 2023
Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.

Monika Raab, Izabela Kostova, Samuel Peña-Llopis

|Jul 24, 2023
Correction: A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1.

Monika Raab, Yves Matthess, Christopher A Raab

|Feb 22, 2023
Correction: The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer.

Ranadip Mandal, Monika Raab, Franz Rödel

Pageof 3

Frequent Collaborators

8 joint publications

Mourad Sanhaji

4 joint publications

Ranadip Mandal

4 joint publications

Franz Rödel

4 joint publications

Samuel Peña-Llopis